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Abstract
Background: Chemotherapy in cancer patients can be associated with serious short- and
long-term adverse neurological effects, such as leukoencephalopathy and cognitive impair-
ment, even when therapy is delivered systemically. The underlying cellular basis for these
adverse effects is poorly understood.
Results: We found that three mainstream chemotherapeutic agents - carmustine (BCNU),
cisplatin, and cytosine arabinoside (cytarabine), representing two DNA cross-linking agents
and an antimetabolite, respectively - applied at clinically relevant exposure levels to cultured
cells are more toxic for the progenitor cells of the CNS and for nondividing oligodendrocytes
than they are for multiple cancer cell lines. Enhancement of cell death and suppression of cell
division were seen in vitro and  in vivo. When administered systemically in mice, these
chemotherapeutic agents were associated with increased cell death and decreased cell
division in the subventricular zone, in the dentate gyrus of the hippocampus and in the corpus
callosum of the CNS. In some cases, cell division was reduced, and cell death increased, for
weeks after drug administration ended.
Conclusions: Identifying neural populations at risk during any cancer treatment is of great
importance in developing means of reducing neurotoxicity and preserving quality of life in
long-term survivors. Thus, as well as providing possible explanations for the adverse neuro-
logical effects of systemic chemotherapy, the strong correlations between our in vitro and in
vivo analyses indicate that the same approaches we used to identify the reported toxicities can
also provide rapid in vitro screens for analyzing new therapies and discovering means of
achieving selective protection or targeted killing.
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One of the disturbing findings to emerge from studies on
cancer survivors is the frequency with which chemotherapy
is associated with adverse neurological sequelae. Adverse
neurological effects associated with treatment of both child-
hood and adult cancers range from abnormalities detected
by CNS imaging (for example, damage to white matter)
[1-3] to clinical symptoms. Neurological complications
observed as a consequence of chemotherapy include leuko-
encephalopathy, seizures, cerebral infarctions, and cognitive
impairment [4-10].
While it is perhaps not surprising that neurotoxicity occurs
after localized delivery of chemotherapeutic agents to the
CNS, it is increasingly apparent that this is also a substantial
problem associated with the systemic delivery of these
agents for treatment of non-CNS tumors [11-18]. For
example, current data suggest that 18% of all breast cancer
patients receiving standard-dose chemotherapy show
cognitive defects on post-treatment evaluation [19], and
such problems were reported in more than 30% of patients
examined two years after treatment with high-dose chemo-
therapy [7,8], a greater than eightfold increase over the
frequency of such changes in control individuals. Even these
numbers may be underestimates of the frequency of adverse
neurological sequelae in association with aggressive chemo-
therapy, as two longitudinal studies on breast cancer patients
treated with high-dose chemotherapy with carmustine
(BCNU), cisplatin, and cyclophosphamide, and evaluated
using magnetic resonance imaging and proton spectro-
scopy, have shown that changes in white matter in the CNS
induced by the treatment could occur in up to 70% of
individuals, usually with a delayed onset of several months
after treatment [1,2]. Even if examination of all cancers were
to lower the frequency of these problems to 25% of the
lower estimates (that is, around 4.5% of patients receiving
low-dose therapy and 7.5% of patients receiving high-dose
chemotherapy) the prevalence of cancer in the world’s
populations means that the total number of individuals for
whom adverse neurological changes are associated with
cancer treatment is as great as for many of the more widely
recognized neurological syndromes.
Despite the clear evidence of the neurotoxicity of at least
some forms of chemotherapy, studies on the effects of
chemotherapeutic compounds on brain cells are
surprisingly rare. For example, it is known that application
of methotrexate directly into the ventricles of the brain is
associated with ventricular dilation, edema, and the visible
destruction of the ependymal cell layer lining the ventricles
and the surrounding brain tissue [20]. Application of
cytosine arabinoside (cytarabine) onto the surface of the
brain is also associated with adverse effects on the dividing
cells of the subventricular zone of the CNS [21]. In vitro
studies [22] have also shown that oligodendrocytes are
vulnerable to killing by carmustine (BCNU, an alkylating
agent used in the treatment of brain tumors, myeloma, and
both Hodgkin and non-Hodgkin lymphoma) at doses that
would be routinely achieved during treatment. In general,
however, relatively little is known about the effects of
chemotherapeutic agents on the cells of the CNS, in striking
contrast to the extensive investigations on the effects of
irradiation on the brain.
To investigate the biological basis of the adverse neurological
consequences of chemotherapy, we posed the following
questions. Which cells are vulnerable? Is vulnerability
restricted to dividing cells? Does toxicity reflect a direct action
of chemotherapeutic agents on defined neural populations?
How does the sensitivity of primary neural cells compare
with that of cancer cells? What are the in vivo effects of
chemotherapy on the dividing populations of the CNS? Do
chemotherapeutic agents with different modes of action
target the same or different populations of normal cells?
Results
Neural progenitor cells are more vulnerable to DNA
cross-linking agents in vitro than are many cancer
cell lines
To determine the sensitivity of CNS cells to chemothera-
peutic agents, we first exposed a large variety of cell types to
BCNU and cisplatin, of which the former is primarily used
for treating brain cancers and Hodgkin’s lymphoma and the
latter is used to treat a wide range of cancers (including
breast, lung and colon cancers, multiple myeloma and
Hodgkin’s lymphoma). Both agents have been associated
with significant CNS toxicity in patients [11,23-25].
Cisplatin is an alkylating agent thought to work primarily
through forming intrastrand crosslinks between adjacent
purine bases [26], whereas the nitrosourea BCNU causes
primarily interstrand crosslinking between guanine and
cytosine [27]. To ensure that we analyzed the direct effects of
these compounds on potential target cells, we applied BCNU
or cisplatin to purified populations of neuroepithelial stem
cells (NSCs, which generate all neural cells of the CNS [28]),
neuron-restricted precursor (NRP) cells (which generate
neurons but not glia [29]), glial-restricted precursor (GRP)
cells (which generate the macroglia of the CNS but not
neurons [30]), and oligodendrocyte-type-2 astrocyte (O-2A)
progenitor cells (also referred to as oligodendrocyte
precursor cells, and here abbreviated as O-2A/OPCs, the
direct ancestors of oligodendrocytes [31]), astrocytes, and
oligodendrocytes (the myelin-forming cells of the CNS) (all
summarized in Figure 1). We also analyzed human NSCs
and GRP cells [32] and human tumor cell lines from uterine
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(ES-2) cancers, a meningioma cell line and several glioma
cell lines (1789, T98, UT-12, UT-4). Methodological
information is given in the Materials and methods.
Clinically relevant concentrations of BCNU or cisplatin
were more toxic for lineage-committed progenitor cells and
for NSCs than they were for cancer cells. For example,
exposure to 1 µM cisplatin or 25 µM BCNU caused 60-90%
reductions in the viability of O-2A/OPCs and NRP cells
(Figure 2), but had little effect on most of the cancer cell
lines examined. The toxicity of cisplatin was extensive even
at concentrations as low as 0.1 µM, killing 40% or more of
the populations of O-2A/OPCs, oligodendrocytes, and NRP
cells at this low exposure. Exposure to 5 µM BCNU was also
toxic for O-2A/OPCs, NRP cells, and oligodendrocytes.
Thus, these sensitivities were observed at exposure levels
corresponding to the low range of concentrations in
cerebrospinal fluid (CSF) associated with cancer treatment.
These are as low as 0.6-2.8 µM for low-dose intravenous
applications of cisplatin [33] and 8-10 µM for similar
applications of BCNU [34,35], and can be up to two orders
of magnitude or greater in high-dose applications [36-40].
Increasing cisplatin or BCNU concentrations to levels that
killed 40-80% of cancer cells caused 70-100% reduction in
viability of O-2A/OPCs, GRP cells, NRP cells, and NSCs
(Figure 3). The preferential vulnerability of both rat and
human primary CNS progenitor cells to BCNU and cisplatin
was apparent also at very low exposure levels. Even the BCNU-
and cisplatin-responsive ES-2 ovarian cancer cell line was only
as vulnerable as normal CNS progenitors. Thus, in examining
tumors of a wide range of sensitivities, we could not identify
any populations that exceeded the vulnerability of neural
precursor cells to damage induced by cisplatin or BCNU.
One of the unexpected findings to emerge from our studies
was that the vulnerability of CNS cells to BCNU and
cisplatin was not restricted to rapidly dividing cells, as
nondividing oligodendrocytes were as sensitive as neural
progenitors to BCNU and cisplatin, consistent with our
previous studies on vulnerability of oligodendrocytes to
BCNU [22]. Thus, contrary to the widely held view that the
toxicity of chemotherapeutic agents is primarily directed
against dividing cells, the ability of BCNU and cisplatin to
damage normal cell types in the CNS was not limited to
rapidly dividing progenitors. Moreover, cell division by
itself was not sufficient to confer vulnerability, as rapidly
dividing NSCs were more resistant than progenitor cells. Of
all the CNS cell types examined, only astrocytes were as
resistant as cancer cells. Thus, the major targets of cisplatin
and BCNU toxicity appear to be lineage-restricted
progenitor cells and nondividing oligodendrocytes.
Sub-lethal doses of chemotherapy reduce the
self-renewal of O-2A/OPCs
Normal progenitor cell function also requires cell division,
both during development and for purposes of repair. For O-
2A/OPCs, where division can be followed over several days
in sensitive clonal assays, it is known that agents that can be
cytotoxic at high concentrations will induce cessation of
division and induction of differentiation when applied at
sublethal dosages [41]. We therefore asked whether sub-
lethal concentrations of cisplatin and BCNU compromised
progenitor cell proliferation. These assays were conducted on
O-2A/OPCs in order to benefit from the ability to examine
proliferation and differentation at the clonal level [41-43].
Transient exposure of O-2A/OPCs to concentrations of
cisplatin or BCNU that did not cause significant cell death
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Figure 1
Schematic representation of the lineage relationships of the cell types
examined in these studies. Pluripotent neuroepithelial stem cells (NSC)
give rise to glial-restricted precursor (GRP) cells and neuron-restricted
precursor (NRP) cells. NRP cells can give rise to multiple populations
of neurons, whereas GRP cells give rise to astrocytes and
oligodendrocyte-type-2 astrocytes (O-2A/OPCs). The O-2A/OPCs in
turn give rise to oligodendrocytes. The progenitor cells that lie
between NSCs and differentiated cell types, and are the major dividing
cell population in the CNS, appear to be exceptionally vulnerable to the
effects of chemotherapeutic agents. Also sharing this vulnerability are
nondividing oligodendrocytes.
NSC
GRP cells NRP cells
O-2A/OPC
Astrocytes
Neurons
Oligodendrocytes(0.05 µM cisplatin or 2.5 µM BCNU) was associated with
reduced cell division and increased differentiation into
oligodendrocytes (Figure 4). In control cultures, for
example, 35% of the cells were dividing progenitors after
seven days, and more than 25% of clones contained three
or more progenitors. In striking contrast, in cultures
exposed to 2.5 µM BCNU for just 1 hour after the first day
of in vitro growth and then followed for an additional seven
days, only 6% of cells were progenitors and no clones
contained more than two progenitor cells. Similar
observations were seen at earlier time points and also with
transient application of cisplatin to O-2A/OPCs (data not
shown). Thus, even when cell death is not evident, these
agents may compromise progenitor cell division. As average
clonal sizes in the BCNU-exposed versus control cultures at
day 7 were not significantly different (3.3 ± 2.3 vs 3.6 ± 2.3
cells per clone in BCNU-treated vs control cultures,
respectively;  P = 0.55), it seems that the very low
concentration of BCNU examined in these studies is
sufficient to shift the balance between division and
differentiation far enough in the direction of
oligodendrocyte generation to have a cumulative effect over
multiple cellular generations, but not to immediately cause
cell-cycle exit. As considered in the Discussion, these results
are much like those seen in our ongoing studies on the
regulation of the balance between division and
differentiation by intracellular redox state and by signaling
molecules that make O-2A/OPCs more oxidized. The
possibility that this effect of exposure to very low
concentrations of BCNU (along with cisplatin and, as
shown later, cytarabine) is related to oxidative changes is
considered in the Discussion.
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Figure 2
Primary CNS cells are more vulnerable to BCNU and cisplatin than are cancer cells. Cells were plated on coverslips in 24-well plates at a density of
1,000 cells per well and allowed to grow for 24-48 h. On the basis of drug concentrations achieved in human patients, cells were exposed to 
(a) cisplatin (1 M; for 20 h) or (b) BCNU (25 M; for 1 h). Cell survival and viability was determined after additional 24-48 h (see Materials and
methods). The rat neural cell types studied included O-2A/OPCs, oligodendrocytes, NRP cells, GRP cells, NSCs, and astrocytes. The normal human
neural cell types consisted of human GRP and neuroepithelial precursor cells (human NEP). The tumor cells studied were the human malignant
glioma cells UT-4, UT-12, and 1789, the colon cancer cell lines HT-29 and SW480, a meningioma cell line (Men-1), breast cancer cells (MCF-7),
uterine cancer cells (MES), and ovarian cancer cells (ES-2). Each experiment was carried out in quadruplicate and repeated multiple times in
independent experiments. Data represents mean of survival ± SEM, normalized to control values.
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Figure 3 (see figure on following page)
Sensitivity of rat and human-derived CNS cells and human cancer cells to BCNU or cisplatin. Cells were treated with (a,c,e,g) cisplatin and
(b,d,f,h) BCNU over a wide dose range (0.1-100 M and 5-200 M, respectively). Each experiment was carried out in quadruplicate and repeated
multiple times in independent experiments. Data represents mean of survival ± SEM, normalized to control values. There are no concentrations of
either drug for which tumor cell lines were more sensitive than the more sensitive neural progenitor cells and oligodendrocytes.http://jbiol.com/content/5/7/22 Journal of Biology 2006, Volume 5, Article 22 Dietrich et al. 22.5
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Figure 3 (see legend on the previous page)In vivo effects of BCNU and cisplatin on cell death
and cell division in the CNS
Analyses  in vivo confirmed that precursor cells and oligo-
dendrocytes were also adversely affected by chemotherapeutic
agents when systemically applied to living animals, and that
these adverse effects continued beyond the period of
chemotherapy exposure. In these experiments we treated
mice with BCNU or cisplatin and examined cell death and
cell division in the CNS. Treatment with three injections of
BCNU (10 mg/kg each, given intraperitoneally (i.p.) on
days 1, 3, and 5) was associated with significantly increased
cell death for at least 6 weeks after treatment (Figure 5).
Analysis using the terminal deoxynucleotidyltransferase-
mediated dUTP nick-end labeling (TUNEL) assay for
apoptotic cells (see Materials and methods) 1 day after
completion of treatment revealed a 16.1-fold increase in the
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Figure 4
A low dose of BCNU decreases division and promotes differentiation of O-2A/OPCs. Cells grown at clonal density were exposed 1 day after plating
to low-dose BCNU (2.5 M for 1 h), a dosage that did not cause significant killing (< 5%) of O-2A/OPCs in mass culture. The number of
undifferentiated O-2A/OPCs and differentiated cells (oligodendrocytes) was determined in each individual clone from a total number of 50 clones in
each condition by morphological examination and by immunostaining with A2B5 and anti-GalC (galactocerebroside) antibodies (to label O-2A/OPCs
and oligodendrocytes, respectively). (a) Schematic diagram of the differentiation potential of O-2A/OPCs. Bipolar O-2A/OPCs can undergo
continued cell division(s) to form new precursor cells (red), and can differentiate into multipolar postmitotic oligodendrocytes (green). Alternatively,
an O-2A/OPC can differentiate directly into an oligodendrocyte without further cell divisions. (b) An example of one clone in culture.
Immunostaining with A2B5 (red) and anti-GalC (green) identifies six O-2A/OPCs and two oligodendrocytes. Cell nuclei stained in blue (DAPI). Scale
bar represents 20 m. (c) Composition of progenitors and oligodendrocytes in a representative experiment of control cultures analyzed 8 days
after plating optic nerve-derived O-2A/OPCs at clonal density. Multiple clones with three or more O-2A/OPCs were seen. (d) In parallel
BCNU-treated cultures, analyzed 8 days after plating at clonal density (7 days after BCNU exposure), no clones contained more than two
O-2A/OPCs. Experiments were performed in triplicate in at least two independent experiments. In the experiments represented in (c) and (d) the
proliferation and differentiation of O-2A/OPCs were followed over a time course of up to 10 days after BCNU treatment. Results are presented as
representative three-dimensional graphs. The number of progenitors per clone is shown on the x (horizontal) axis, the number of oligodendrocytes
on the z (orthogonal) axis and the number of clones with any particular composition on the y (vertical) axis.
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(c) (d)number of TUNEL+ cells in the subventricular zone (SVZ), a
13.3-fold increase in the corpus callosum (CC), and a
3.8-fold increase in the dentate gyrus (DG) of the hippo-
campus. Ten days after the last injection there were still
increased numbers of TUNEL+ cells in all regions examined,
and this increase was maintained in the SVZ for at least 6
weeks post-treatment (P < 0.04). Thus, application of BCNU
was associated with the induction of an extended period of
increased cell death.
Cisplatin (5 mg/kg i.p., days 1, 3, and 5) was similar to
BCNU in its effects on the DG, and was associated with a
prolonged two- to threefold increase in the number of
TUNEL+ cells, persisting at least 42 days, compared with
sham-injected control animals. In contrast to BCNU, how-
ever, cisplatin was associated with only a modest increase in
the number of TUNEL+ cells in the CC at 10 days post-
treatment (Figure 5), and with no significant increases in
apoptotic cells in the SVZ.
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Figure 5
Systemic chemotherapy leads to increased and prolonged cell death in the adult mouse CNS. Cell death was determined using the terminal
deoxynucleotidyltransferase-mediated dUTP nick-end labeling (TUNEL) assay. The number of TUNEL+ cells was analyzed in control animals (which
received 0.9% NaCl i.p.) and chemotherapy-treated animals and presented as percent normalized values of controls. Each treatment group consisted
of n = 5 animals, including control groups at each time point. (a) Animals that received three BCNU (left panel) or cisplatin (right panel) injections
(10 mg/kg or 5 mg/kg, respectively, on days 1, 3, and 5) show marked and prolonged increases in cell death in the lateral subventricular zone (SVZ),
the corpus callosum (CC) and the dentate gyrus (DG) at 1, 10, and 42 days following treatment (n = 5 animals per group). *P < 0.01. (b) Co-analysis
of TUNEL labeling with antigen expression reveals that the great majority of TUNEL+ cells in the SVZ and DG are doublecortin+ (DCX+) neuronal
progenitors [44], and that other TUNEL+ cells include GFAP + cells (which may be stem cells or astrocytes [45]) and NG2+ progenitor cells [46]. In
the CC, in contrast, the TUNEL+ cells were NG2+ glial progenitor cells [47], CNPase+ (CNP+) oligodendrocytes or GFAP+ astrocytes. Co-labeling
for TUNEL and myelin basic protein expression revealed results similar to CNPase analysis. Note that close to 100% of TUNEL+ cells are accounted
for by known lineage markers.
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*To determine whether acute treatment with chemotherapy
has the same cellular targets in vivo as  in vitro, we
combined the TUNEL assay with labeling with cell-type
specific antibodies, and analyzed individual cells by
confocal microscopy. In order to focus on the immediate
targets of the chemotherapy, analysis was conducted
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Figure 6
Representative images of co-labeling for TUNEL and expression of cell type-specific antigens. Despite the apparent labeling of nuclei with cell-type
specific antibodies in dying cells (presumably due to the changes in antigen distribution associated with nuclear fragmentation), co-labeling was highly
cell-type specific (see also Figure 7 for z-stack analysis). (a-d) NG2+/TUNEL+ cells from the CC. In this and subsequent rows, the first image is of
TUNEL staining, the next two images are of staining for the proteins indicated, and the merged image is on the far right. (e-h) DCX+/TUNEL+ cells
from SVZ; (i-l) GFAP+/TUNEL+ cell from DG. (m-p) NeuN+/TUNEL+ cell from DG. In all merged images except (l) co-labeled cells show up as
yellow; in (l) the nucleus of the co-labeled cell is green. Magnification 400x.
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TUNELin animals sacrificed 1 day after the completion of
BCNU treatment.
Confocal microscopic analysis of immunolabeling and
TUNEL staining confirmed the vulnerability of precursor
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Figure 7
Representative z-stack of TUNEL+/doublecortin+ cells. Photographs were taken at 2 m intervals. Identical analyses were conducted for every cell
that was scored as TUNEL+ and expressing a cell type-specific antigen, as shown in Figure 4. Each row shows, from left to right, TUNEL staining,
doublecortin staining, S-100b staining, and the merged image. (a-d) Images taken at -4 µm; (e-h) -2 µm; (i-l) 0 µm; (m-p) 2 µm. The congruence
between the doublecortin+ staining and the TUNEL+ nuclei (which shows up as yellow in the merged image) was presumably due to the changes in
antigen distribution associated with nuclear fragmentation, as this was always cell-type specific in that there was overlap only in those cases in which
the rest of the cell was also stained with the same antibody. For example TUNEL+/doublecortin+ cells were always doublecortin+ in the cytoplasm,
and other antibodies used in the same sections did not label the TUNEL-labeled nuclei of doublecortin+ cells.
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(g)cells and oligodendrocytes in vivo (Figures 5-7). Untreated
animals harbored only very rare TUNEL+ cells, but such cells
were frequently found in the SVZ, DG, and CC of animals
receiving chemotherapy. In the SVZ and DG, the majority of
TUNEL+ cells observed after BCNU treatment were neuronal
progenitors positive for the protein doublecortin (DCX)
[44], followed by cells positive for glial fibrillary acidic
protein (GFAP) (which may be astrocytes or stem cells
[45]). We also observed co-labeling of a smaller number of
TUNEL+ progenitor cells also positive for the protein NG2
proteoglycan (which would be O-2A/OPCs [46,47]) and, in
the DG, mature neurons positive for neuronal nuclear
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Figure 8
Chemotherapy decreases cell proliferation in the adult mouse CNS. Systemic exposure to cisplatin and BCNU was associated with profound
changes in the number of BrdU-incorporating cells in the lateral SVZ, the DG and the CC. Animals were treated as described in Figure 5. The graphs
show the percent-corrected values of BrdU+ cells per brain area normalized to the number of BrdU+ cells in sham-treated animals at various time
points after systemic treatment with either BCNU or cisplatin. Data are means ± SEM. (a,b) Percent-corrected values of BrdU+ cells after (a) BCNU
treatment or (b) cisplatin treatment. Bars labeled with an asterisk show statistically significant (P < 0.01) differences from control animals. 
(c) Immunoperoxidase staining for detection of BrdU+ cells in the lateral SVZ in representative sections from a 0.9% NaCl-injected control animal
(C), one day (D1), and 42 days (D42) after systemic treatment with BCNU (3 × 10 mg/kg i.p.). (d) Diagrammatic representation of the part of the
SVZ shown in (c) with adjacent part of the striatum (STR) and the overlying CC.
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*anitgen (NeuN). In the CC, most TUNEL+ cells were NG2+
glial progenitors, followed by oligodendrocytes (recognized
by expression of 2,3-cyclic nucleotide-3-phosphodiesterase
(CNPase) or myelin basic protein) and then by GFAP+ cells
(which were most probably astrocytes). In all tissues,
labeling with these lineage markers accounted for the great
majority of all TUNEL+ cells. Thus, the profile of vulner-
ability agrees closely with that indicated by in vitro experi-
ments, with sensitivity to the chemotherapeutic agents seen
in both neuronal and glial progenitor cells, as well as in
oligodendrocytes themselves.
We also examined the incorporation of bromodeoxyuridine
(BrdU) into regions of the CNS in which cell division occurs
in adult animals. Such division is highly restricted in the
adult CNS, occurring only in particular regions and/or cell
types. The SVZ is known to contain dividing cells and
represents the major germinal zone in the CNS [48-51]. The
hippocampus is also a region of continued cell generation
in the adult CNS, with the majority of dividing cells appear-
ing to be neuronal precursor cells [52,53]. White matter
tracts also contain dividing cells that have been charac-
terized as an adult-specific population of O-2A/OPCs.
Although in vitro studies have shown that such cells may
have long cell-cycle times, dividing in vitro over an average
period of 65 hours instead of the 18-hour cell cycle
displayed by O-2A/OPCs isolated from young postnatal rats
[54,55], their frequency in the adult CNS is such that they
actually appear to be the major dividing cell type in this
tissue [56,57].
Analysis of DNA synthesis in vivo, as detected by BrdU
labeling, revealed adverse effects of BCNU treatment in CNS
regions in which cell proliferation in putative germinal
zones is thought to be a critical component of normal tissue
function (that is, the SVZ and the DG [58]), as well as in the
CC (Figure 8a). BCNU treatment caused a reduction in the
number of BrdU-incorporating cells for at least 6 weeks after
the final (third) injection, with either no recovery or a
continued fall in numbers of BrdU+ cells to values 50-80%
below control values. Thus, repetitive exposure to BCNU
caused marked long-term impairments in cell proliferation
in the CNS.
We combined in vivo labeling with BrdU with confocal
analysis to determine whether BCNU preferentially reduced
DNA synthesis in any particular cell population(s), and
found that the distribution of BrdU incorporation between
different cell populations was unchanged by the exposure to
chemotherapy (Table 1). For example, in the CC, 86 ± 2%
of the BrdU-labeled cells were positive for the Olig2 trans-
criptional regulator in control animals (and thus would be
considered to be O-2A/OPCs [59-61]), and 86 ± 12% of the
BrdU+ cells were Olig2+ in BCNU-treated animals. Similarly,
the proportion of BrdU+ cells that were DCX+ (and thus
would be considered to be neuronal precursor cells [44])
was unchanged in the SVZ (38 ± 5% in controls vs 43 ± 5%
in treated animals) and in the DG (70 ± 6% in controls vs.
60 ± 14% in treated animals). Thus, the reduction in cell
division associated with exposure to BCNU (as analyzed by
BrdU incorporation) did not seem to specifically target any
particular population of cells, at least when examined 1 day
after completion of treatment.
Treatment with three injections of cisplatin was also
associated with reduced BrdU incorporation in the SVZ,
DG, and CC when examined 1 day after the final injection
(Figure 8b). In contrast to the effects of BCNU, however, the
number of cells incorporating BrdU returned to normal
levels in the DG and SVZ 6 weeks after treatment. Only in
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Table 1
BCNU affects different neural progenitor cell populations equally in vivo
Cell population SVZ control SVZ BCNU DG control DG BCNU CC control CC BCNU
DCX+ 38 ± 5 43 ± 5 70 ± 6 60 ± 14 ND ND
Olig2+ 14 ± 7 13 ± 13 15 ± 2 15 ± 3 86 ± 2 86 ± 11
S-100β+ 2 ± 4 2 ± 3 10 ± 6 2 ± 3 10 ± 6 14 ± 11
In these experiments, BrdU-labeled cells were co-analyzed for expression of cell-type specific antigens by confocal microscopy, as in Figures 5-7, for
the same animals as were analyzed for Figure 5. All cells were analyzed by z-stack analysis to confirm identity of the BrdU+ incorporation and labeling
with cell-type specific antibodies. Numbers are provided as average percentages ± SEM of all BrdU+ cells identified for each animal, as described in
Materials and methods. DCX expression was not analyzed (ND) in the corpus callosum (CC), because of the lack of neuronal progenitor cells in
white-matter tracts. The data show that, despite the reduction in total numbers of BrdU+ cells in each tissue, each individual cell population was
affected similarly, and did not change in its proportional contribution to the entire population of BrdU+ cells. The only possible exception to this is
the representation of BrdU+ GFAP+ cells in the dentate gyrus (DG), but the difference between this set and controls did not achieve significance.
SVZ, subventricular zone.the CC was the number of BrdU+ cells still reduced at this
late time point.
Cytarabine also exhibits preferential toxicity for
CNS progenitor cells and oligodendrocytes,
compromises cell division in vitro, and causes cell
death and reduced cell division in vivo
To determine whether the effects seen so far were specific
for DNA crosslinking agents, we extended our studies to
include the antimetabolite cytarabine, which is commonly
used in treating leukemia and lymphomas, and also has
been associated with adverse neurological effects [25,62].
Like cisplatin and BCNU, concentrations of cytarabine
routinely achieved in the clinic were highly toxic for neural
progenitor cells in vitro. Cerebrospinal fluid concentrations
of cytarabine during conventional treatments are in the
range 0.1-0.3 µM, are ten times higher in high-dose applica-
tions, and can be 10,000 times higher following intrathecal
application [63]. Exposure of primary neural cells to 0.1 µM
cytarabine (equivalent to concentrations achieved in low-
dose therapeutic utilization) for 24 hours killed more than
60% of O-2A/OPCs (Figure 9a). At this lower level of
exposure, O-2A/OPCs were markedly more sensitive to the
effects of cytarabine than were L1210 lymphocytic leukemia
and EL-4 lymphoma cells - examples of tumor populations
for which cytarabine would be used (Figure 9b). Exposure to
1 µM cytarabine (equivalent to the lower range of
concentrations achieved in high-dose therapeutic
applications, and an effective concentration for killing the
L1210 and EL-4 cells) killed most O-2A/OPCs and around
50% of GRP cells.
Like cisplatin and BCNU, cytarabine toxicity was not
limited to dividing cells, nor did it affect all dividing
populations. Treatment for 24 hours with 0.1 µM of cytara-
bine induced a 2.4 ± 0.06-fold increase in the percentage of
apoptotic TUNEL+ oligodendrocytes, and treatment with
2 µM cytarabine for 24 hours killed 82.4 ± 5.8% of oligo-
dendrocytes (data not shown). As these cells were not
dividing in the culture conditions used, the toxicity of
cytarabine also extends beyond division-dependent effects.
Also as with cisplatin and BCNU, purified astrocytes and
NSCs (which were dividing rapidly in the culture conditions
used) were less sensitive to the effects of cytarabine,
although even these populations were adversely affected by
the millimolar concentrations (data not shown) achieved
with intrathecal administration.
As with BCNU and cisplatin, exposure to sublethal concen-
trations of cytarabine was associated with suppression of
O-2A/OPC division in clonal assays. In these experiments,
O-2A/OPCs were exposed to 0.01 µM cytarabine (a concen-
tration equivalent to 10% or greater than that found in the
cerebrospinal fluid in standard-dose applications of this
chemotherapeutic agent [63]). Cytarabine was washed out
after 24 hours, after which cultures were followed for
5 days. As shown in Figure 10, this transient exposure was
not incompatible with continued division or survival, but
was associated with a marked increase in the contribution
of clones consisting of just one or two oligodendrocytes and
no progenitor cells (with 16 out of 100 such clones seen in
control cultures and 42 of 100 in those transiently exposed
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Figure 9
Primary CNS cells are equally or more vulnerable to cytarabine than
cancer cells. Cells were plated on coverslips in 24-well plates at a
density of 1,000 cells per well and allowed to grow for 24-48 h. On the
basis of drug concentrations achieved in human patients, cells were
exposed to cytarabine for 24 h. Cell survival and viability was
determined after additional 24-48 h (see Materials and methods). 
(a) Rat neural cell types studied included O-2A/OPCs,
oligodendrocytes, GRP cells, NSCs and astrocytes. (b) We also
examined the T98 glioma cell line, a meningioma cell line, and the
L1210 and EL-4 leukemia cell lines. To define the onset of cytarabine
toxicity, cells were treated with cytarabine over a wide dose range
(0.01-1 µM) extending downwards from the lower ranges achieved in
high-dose therapy. Each experiment was carried out in quadruplicate
and was repeated multiple times in independent experiments. Data
represent mean of survival ± SEM, normalized to control values. There
are no concentrations of cytarabine at which tumor cell lines were
more sensitive O-2A/OPCs or oligodendrocytes.
T98 glioma
Meningioma
L1210 (leukemia)
EL-4 (lymphoma)
0 0.01 0.1
Cytarabine (µm)
Cytarabine (µm)
1
0.001 0 0.1 1
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
O-2A/OPC
NSC
GRP
Oligodendrocytes
Astrocytes
0
20
40
60
80
100
120
0
20
40
60
80
100
120
(a)
(b)to 0.01 µM cytarabine). Moreover, there was also a
reduction in the number of clones containing eight or more
progenitors (with 13 of 100 such clones in control cultures
and 4 out of 100 in cytarabine-treated cultures), along with
a more general shift towards clones with fewer progenitor
cells. Despite the adverse effects of even low-dose cytarabine
on oligodendrocytes (Figure 9), transient exposure of
O-2A/OPCs to cytarabine did not prevent the subsequent
generation of oligodendrocytes, as shown in Figure 10.
Systemic treatment with cytarabine in vivo was associated
with adverse effects on the CNS, in regard to both cell death
and cell division (as indicated by BrdU incorporation).
TUNEL staining was elevated in the SVZ, DG, and CC
following treatment of mice with three injections of
cytarabine (250 mg/kg, i.p., days 1, 3, and 5, as routinely
used in mice [64]). Significantly greater numbers of TUNEL+
cells were still found in the SVZ 56 days after the final
treatment, and in the DG and CC on 1 and 14 days after
treatment ended (Figure 11). The number of BrdU+ cells
was reduced in the SVZ at 1, 14, and 56 days after treat-
ment, and was lower in the CC at all time points. DNA
synthesis in the DG was significantly reduced below control
levels only at the late time point of 56 days after the final
cytarabine injection.
Examining the effects of cytarabine on different cell
populations, we found that both neuronal precursors [44]
and oligodendrocyte precursors were affected in vivo. In the
CC, where there was around 50% reduction in the number
of BrdU+ cells observed in tissue sections from animals
sacrificed 1 day after the completion of treatment, the
proportion of BrdU+ cells that were Olig2+ (that is, were
oligodendrocyte precursor cells [59-61]) was no different
between controls and treated animals (Figures 12-14). This
result held true also at day 56, when the proportionate
representation of Olig2+ cells among the BrdU+ population
was unchanged both in untreated and treated animals,
despite a continued 50% reduction in the total number of
BrdU+ cells observed.
In contrast with effects on Olig2+/BrdU+ populations in the
CC, our analyses raise the possibility of a somewhat
enhanced loss of DCX+ cells from among the BrdU+ popula-
tion in both the SVZ and DG (Figure 12). In the SVZ, at 1
day after treatment, there was a disproportionate and
significant reduction in the percentage of DCX+/BrdU+ cells,
which represented 50 ± 3% of the cells incorporating BrdU
in control animals and only 28 ± 8% in animals treated
three times with cytarabine. This disproportionate reduction
in the percentage of BrdU+ cells that was DCX+ did not
seem, however, to be maintained over time in the SVZ, and
at day 56 the proportion of BrdU+ cells that were DCX+ was
not different in controls versus treated animals. In contrast,
in the DG, a reduction in representation of DCX+ cells was
also seen, except that in this case there was a marked 60%
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Figure 10
Low-dose cytarabine decreases division and promotes differentiation of
O-2A/OPCs. Cells grown at clonal density were exposed 1 day after
plating to low-dose cytarabine (0.01 µM for 24 h), a dosage that killed
less than 5% of O-2A/OPCs in mass culture (Figure 9). The number of
undifferentiated O-2A/OPCs and differentiated cells (oligodendrocytes)
was determined in each individual clone from a total of 100 clones in
each condition by morphological examination and by immunostaining
with A2B5 and anti-GalC antibodies (to label O-2A/OPCs and
oligodendrocytes, respectively), as in Figure 4. (a) Composition of
progenitors and oligodendrocytes in a representative experiment of
control cultures analyzed 6 days after plating optic nerve-derived
O-2A/OPCs cells at clonal density. (b) In parallel cytarabine
(Ara-C)-treated cultures analyzed 6 days after plating at clonal density
(5 days after the start of cytarabine exposure), there was a marked
increase in the representation of small clones consisting wholly of
oligodendrocytes, a reduction in the representation of large clones, and
a general shift of clone size towards smaller values. Experiments were
performed in triplicate in at least two independent experiments.
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(b)reduction in the proportion of BrdU+ cells that were DCX+
when day 56 results were compared with either controls of
the same age or the proportionate representation of this
population at day 1 after injury.
In the SVZ and the DG, cytarabine application was also
associated with an increased representation of GFAP+ cells
among the BrdU-incorporating populations. This increased
representation of GFAP+ cells was seen at both day 1 and
day 56 in the SVZ and on day 56 in the DG. In addition,
BrdU+ cells that did not label with any of the cell-type-
specific antibodies used in these studies were more
prominent in treated animals than in controls at day 1 (but
not at day 56) in the SVZ, and were found in the DG at both
time points (data not shown). The only tissue in which
these unlabeled cells provided a greater than 10% contri-
bution to the entire BrdU+ population was in the DG. Such
cells represented around 2% and around 20% of the BrdU-
labeled cells at days 1 and 56, respectively, of all BrdU-
labeled cells in control animals versus around 15% and
about 35% (for days 1 and 56, respectively) of the entire
BrdU+ population in the treated animals.
Discussion
We found that normal neural progenitor cells and oligo-
dendrocytes of the CNS are exceptionally vulnerable to the
toxic effects of the chemotherapeutic agents BCNU, cisplatin,
and cytarabine. Vulnerability to these drugs was observed for
all classes of lineage-restricted progenitor cells that can be
readily grown as purified cell populations. Moreover,
vulnerability was not restricted to dividing cells, as
nondividing oligodendrocytes were also targets of these
drugs, at exposure levels routinely achieved during treatment.
In vitro analyses of purified cell populations were highly
predictive of effects seen following systemic treatment with
any of the chemotherapeutic agents in vivo. Comparative
analysis of multiple cancer cell lines from different tissues
only identified one cell line in which vulnerability was
comparable to that observed for primary neural progenitor
cells, with most such cell lines being more resistant to these
agents than the normal cells (despite often being chosen
because of their previous use in studies on the response to the
drugs studied). Thus, it appears that the vulnerability of
multiple normal cell populations of the CNS to cisplatin,
BCNU, and cytarabine rivals the vulnerability of cancer cells
themselves. The fact that toxicities for neuronal precursors,
glial precursors, and oligodendrocytes, and toxicity in three
different regions of the CNS, are associated with systemic
application of chemotherapeutic drugs is of particular
concern, as such toxicity would be applicable to treatment of
all forms of cancer. Moreover, our studies demonstrate that
the adverse effects of systemic application are not limited to
the classes of DNA crosslinking agents represented by BCNU
and cisplatin, but also are observed with the antimetabolite
cytarabine. Thus, the adverse effects observed in the present
studies may be relevant in understanding the side effects of
multiple classes of chemotherapeutic drugs.
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Figure 11
Systemic chemotherapy with cytarabine leads to increased and
prolonged cell death, and decreased BrdU incorporation, in the adult
mouse CNS. Cell death and BrdU incorporation were examined as in
Figures 5 and 8. (a) The number of TUNEL+ cells was analyzed in
control animals and is presented as percent normalized values of
controls. Each treatment group consisted of n = 5 animals, including
control groups at each time point. Animals that received three
cytarabine injections (250 mg/kg on days 1, 3, and 5 leading up to the
analysis, where day 1 of analysis equals one day after the last treatment
with cytarabine) show marked increases in cell death in the SVZ, CC
and DG at various time points after treatment (n = 5 animals per
group). (b) BrdU analysis. Animals were treated as for (a). As in Figure
8, the graphs show the percent BrdU+ cells per brain area normalized
to the number of BrdU+ cells in sham-treated animals at various time
points after systemic treatment with cytarabine. Data are means ± SEM;
*P < 0.01 in comparisons with control animals.
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(b)This is the first study of which we are aware that demonstrates
that neural progenitor cells and oligodendrocytes are
exceptionally vulnerable to the action of chemotherapeutic
drugs in vitro and in vivo, even when applied extra-cranially.
This study also suggests that, at least in the CNS, it is
progenitor cells and not stem cells that are the most
vulnerable targets. Adverse effects are known to occur
clinically with all the agents we studied, both acutely and as
delayed neurotoxicities (such as cognitive impairment) that
may only become apparent years after treatment. For example,
BCNU treatment has been associated with significant changes
in mental status and with white matter degeneration [23,24].
Cisplatin at high doses has been associated with
leukoencephalopathy and destruction of CNS white matter
[25]. Application of cytarabine, the third drug examined in
our studies, has also been associated with acute
encephalopathy, confusion, memory loss, and white matter
changes [25,62]. The vulnerability of neural progenitor cells
and oligodendrocytes to these drugs, which was also observed
in our antigenic analysis of TUNEL-labeled cells in the CNS of
animals exposed to BCNU in vivo and BrdU-labeled cells
exposed to either BCNU or cytarabine, may provide an
explanation for the neurotoxic consequences of the treatments
and also may be relevant to understanding long-term
toxicities. It was particularly striking that O-A/OPCs and
oligodendrocytes were one to two orders of magnitude more
sensitive to cisplatin or cytarabine than has previously been
observed in studies on multiple neuronal populations from
both the CNS and the peripheral nervous system [65-70].
The toxicities seen in our studies occurred well within the
concentration ranges achieved for these agents in CSF
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Figure 12
Co-analysis of BrdU incorporation with antigen expression indicates that division of both DCX+ neuronal progenitors and Olig2+ oligodendrocyte
precursors is reduced by systemic exposure to cytarabine. In the CC, where there was an approximately 50% reduction in the number of BrdU+
cells (see Figure 11b), the proportion of BrdU+ cells that were Olig2+ was no different between controls and treated animals on either day 1 
((a) control; (b) cytarabine) or on day 56 ((c) control; (d) cytarabine) after completion of treatment. Thus, the reduction in apparent division of
Olig2+ cells was proportionate to the overall reduction in all BrdU+ cells. In contrast with effects on Olig2+ populations in the corpus callosum, our
analyses indicate an enhanced loss of DCX+ cells from among the BrdU+ population in both the SVZ and DG. This was particularly striking in the
DG, where at 56 days post-treatment the proportion of BrdU+ cells in the cytarabine-treated animals was < 40% of that seen in control animals.
Data are means ± SEM; *P < 0.05, **P < 0.01, and ***P < 0.001 in comparisons with control animals.
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(c) (d)during cancer therapy. For example, cisplatin toxicity for
multiple neural cell types was observed at concentrations as
low as 0.1 µM (Figure 3). CSF concentrations for cisplatin in
conventional or low-dose intravenous applications are bet-
ween 0.6 and 2.8 µM [33] but can reach up to 80 µM in
high-dose applications [36]. Moreover, much higher
concentrations in brain tissue and CSF have been reported
after intra-arterial applications, liposomal encapsulations,
after previous radiation, or in cases of blood-brain barrier
disruption [37,38]. BCNU toxicity was observed at concen-
trations as low as 5 µM. This agent is highly lipophilic, and
about 80% of plasma levels are detectable in CSF and brain
tissue [34]. CSF concentrations of BCNU are in the range of
8-10 µM after intravenous applications [35], but can be
100-1,000-fold higher after local applications via bio-
degradable polymer wafers [39,40]. Similarly, the toxicity of
cytarabine was already apparent at concentrations as low as
0.1 µM or less, compared with CSF concentrations during
conventional treatments in the range of 0.1-0.3 µM, and
concentrations that are ten times higher in high-dose
applications, and 10,000 times higher following intrathecal
application [63].
In vitro studies further indicated that the toxicity of BCNU,
cisplatin, and cytarabine is not limited to the induction of
cell death, but is also associated with the suppression of cell
division of O-2A/OPCs even when applied transiently at
levels that cause little or no cell death, and that represent
small fractions of the CSF concentrations achieved with
systemic chemotherapy. The suppression of division was
particularly striking in that a single transient exposure of
dividing O-2A/OPCs to BCNU, cisplatin, or cytarabine was
sufficient to cause a marked reduction in subsequent cell
division at the clonal level. Such a loss of dividing cells
would compromise the ability of dividing progenitor cells
to contribute to repair processes, and could also contribute
to long-term or delayed toxicity reactions.
The observations that BCNU, cisplatin, and cytarabine all
cause dividing O-2A/OPCs to undergo a greater extent of
oligodendrocyte generation are as predicted from our
studies on the role of intracellular redox state in controlling
the balance between self-renewal and differentiation [41],
and from observations that all three agents cause cells to
become more oxidized [69,71-75]. In our studies on redox
regulation of precursor cell function, we found that O-2A/
OPCs that are slightly (around 20%) more oxidized have a
higher probability of undergoing differentiation, whether
this oxidative status is due to cell-intrinsic mechanisms,
exposure to pharmacological pro-oxidants or to physio-
logical inducers of oligodendrocyte generation (such as
thyroid hormone) [41,43]. Even when this shift in differen-
tiation probability is relatively small [76], cumulative effects
over multiple cell generations can lead to differentiation
outcomes in which clonal composition is clearly different
but in which analysis at delayed time points is required for
the reduction in progenitor cell representation to translate
into markedly smaller clonal sizes.
In vitro studies on purified cell populations appeared to
accurately predict sensitivities observed in vivo. Combined
analysis of TUNEL and antigen expression demonstrated
death of both neuronal and glial precursors, as well as of
oligodendrocytes. Combined analysis of BrdU labeling and
antigen expression similarly revealed reductions in BrdU
incorporation in neuronal precursors of the hippocampus
and in glial precursor cells of the CC. The high level of
correlation between in vitro and in vivo outcomes suggests
that purified populations of the cell types studied can
provide a means of rapidly analyzing other cancer therapies.
Although all chemotherapeutic drugs examined were
associated with toxicity in vivo, there were important
differences between them. BCNU was associated with
particularly severe and prolonged cell death in vivo, while
cell death induced by cisplatin was less severe and
eventually returned to normal values. Cytarabine was
associated with increased cell death for at least 14 days after
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Figure 13
Slice (three-sided) reconstruction of a BrdU+/DCX+ cell. Photographs
were taken at 2 m intervals. Identical analyses were conducted for
every cell that was scored as BrdU+ and expressing a cell-type specific
antigen, as shown in Figure 4. The three-sided reconstruction shows
that the BrdU+ nucleus (green) belongs to the DCX+ cell (red).
BrdU
DCX
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Figure 14
Representative z-stack of a BrdU+/Olig2+ cell. Photographs were taken as for Figure 13. Identical analyses were conducted for every cell that was
scored as BrdU+ and expressing a cell-type specific antigen, as shown in Figure 4. As seen, the BrdU+ nucleus (green) was that of the Olig2+ cell
(blue) indicated by a white arrow. Each row shows, from left to right, BrdU incorporation, staining for Oligo2, and the merged image. Images taken
at (a-c) -4 µm; (d-f) -2 µm; (g-i) 0 µm; (j-l) 2 µm; (m-o) 4 µm.
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(o) (o)treatment ended, with values tending towards or at base-
line levels of TUNEL labeling at 56 days post-treatment.
Whether the less severe effects of cisplatin in this regard
were due to different drug characteristics in terms of blood-
brain barrier permeability is not known (although, in this
regard, it should be noted that cisplatin application in vivo
may actually cause opening of this barrier [77]).
All three agents examined were associated, moreover, with
continued reductions in cell division in one or more CNS
regions after treatment ended, suggesting a long-lasting
depletion of populations required for cell replenishment.
Nonetheless, the fact that some BrdU-incorporating cells
remained in all brain regions examined raises the question of
whether treatments analogous to those used to enhance
bone-marrow function after cancer treatment may be
applicable some day to enhancing the function of the normal
dividing cells of the CNS during or after cancer treatment,
possibly even using the same cytokines that are used to
enhance cell repopulation from the bone marrow [78-80].
The effects of cytarabine on the different cell populations
that incorporated BrdU in vivo were particularly surprising
in the context of previous observations that cytarabine
exposure in vivo (delivered by infusion onto the cortex for
7 days) is associated with a repopulation of the SVZ after
treatment ceases [21,81]. In contrast, our own studies
indicate that this repopulation of dividing cells does not
occur in the CC or DG, and may not endure in the SVZ
(Figure 11). Although previous studies differ from our own
in delivery methods and dosages applied, it may also be
that the capacity for repopulation of dividing cells differs in
different regions of the CNS. Moreover, it may be that the
repopulation of the dividing cells of the SVZ is a transient
phenomenon, as the latest time point examined in our
studies was associated with a fall in the levels of BrdU
incorporation to levels seen 1 day after treatment ended.
Taken together with recent studies on the effects of irradia-
tion on the CNS [82], our results indicate that damage to
CNS progenitor cells is an apparent correlate of both the
main treatments for cancer. Monje et al. [82] suggested that
the adverse effects of irradiation on the hippocampus might
be causally related to the neurological symptoms and
cognitive decline associated with this treatment. This
suggestion would also apply to the effects of chemotherapy.
There are many ways in which the effects of chemotherapy
may be even more of a concern than the effects of irradia-
tion, beginning with the fact that whereas radiation
damage is caused by therapy targeted to the CNS, toxicity
after chemotherapy also occurs after systemic administra-
tion of these compounds. Moreover, our studies also reveal
that the range of CNS cell types vulnerable to the effects of
chemotherapy  is greater than has been studied for
irradiation, and demonstrate toxicity of chemotherapeutic
agents for glial progenitor cells and for oligodendrocytes, as
well as for the hippocampal precursor cells that have been
examined in studies on the effects of irradiation [82]. Yet
another difference between the effects of these two modes
of treatment is that irradiation-associated impairment of
neurogenesis appears to be a secondary effect of inflam-
mation, and can thus be reduced with anti-inflammatory
agents [83]. In contrast, our preliminary analyses of chemo-
therapy-treated animals have not revealed any increased
microglial activation, a hallmark of CNS inflammation
(J. D. and M. N., unpublished work). Thus, there is presently
no reason to think the adverse effects of chemotherapy
might be ameliorated by control of inflammation. The two
sets of studies also differed in severity of outcome, in that
our study reveals a partial fall in the representation of DCX+
neuronal precursor cells whereas the studies on irradiation
revealed a virtually complete lack of neurogenesis [82].
While it will be of interest to extend examination of both
treatment paradigms, it is nonetheless the case that both
studies raise the concern that neurogenesis in the brain is
vulnerable to both forms of cancer treatment.
Our studies have multiple implications for future strategies of
cancer treatment. As doses of BCNU, cisplatin, and cytarabine
that killed even chemosensitive cancer cell lines were equally
or more toxic for neural progenitor cells and
oligodendrocytes, it seems that any concentration of these
chemotherapeutic agents sufficient to harm cancer cells may
also damage many cell populations of the CNS. That cisplatin
may have less severe long-term effects than BCNU might be
construed as encouragement that less toxic treatments can be
developed with existing chemotherapeutic agents. It is also
possible, however, that our results actually understate the
extent of damage that occurs in association with
chemotherapy. Such treatment is typically applied for several
courses over an extended period of time. Furthermore, current
treatment protocols simultaneously apply multiple different
chemotherapeutic agents. This issue is of particular concern in
the light of reports that agents such as cisplatin or BCNU can
cause opening of the blood-brain barrier [77,84], which could
allow entry of adjunctive non-lipophilic agents into the CNS.
In addition, there are multiple therapeutic regimes associated
with higher concentrations of drugs than those we have
studied (for example, intra-arterial administration, liposome-
encapsulated drugs, or locally applied biodegradable wafers in
the treatment of brain tumors). Moreover, the advances that
have been made in rescuing patients from the toxicity of
chemotherapeutic agents for bone marrow have been
associated with a tendency to apply yet higher doses of these
agents, thus potentially increasing the risk of neurotoxicity.
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therapy for the foreseeable future, the potential ramifica-
tions of this work for present and future cancer treatments
seem clear. Plainly, it is of great importance to identify the
neural populations at risk during any cancer treatment in
order to develop means of reducing neurotoxicity and
preserving the quality of life in long-term survivors. This is
an issue of great concern, particularly in the light of recent
studies favoring the use of more aggressive and high-dose
regimens or of newer drugs that target receptor tyrosine
kinase signaling pathways that are critical regulators of
neural progenitor and stem-cell function. In this context, it
will be of particular importance to include more profound
analysis of CNS toxicity in the assessment of new candidate
chemotherapeutic drugs, an evaluation that currently is not
consistently performed. It will also be critical to understand
why some patients have adverse side effects (whether
neurological or non-neurological), whereas others are
spared such damage, and to determine the value of low-
dose (metronomic) therapies [85] in avoiding damage to
the CNS without compromising treatment outcome. In this
regard, it is of concern that our in vitro results raise the
possibility that even exposure to very low levels of these
agents may compromise progenitor cell division. It is clearly
vital to identify therapeutic approaches that do not share
these problems, either by enabling targeted killing of cancer
cells or through selective protection of normal cells during
cancer treatment. The strong correlations between our in
vitro and in vivo analyses indicate that the same approaches
we used to identify the reported toxicities can also provide
rapid  in vitro screens for analyzing new therapies and
discovering means of achieving selective protection or
targeted killing. In light of the ease of use of these in vitro
and in vivo assays, applying them early in the drug-discovery
process may enable a more rapid identification of treat-
ments able to eliminate cancer cells without compromising
the patient’s quality of life.
Materials and methods
Preparation of primary cell cultures
In vitro studies were performed on purified cultures of
primary CNS cells. Multipotent neuroepithelial cell cultures
were prepared from embryonic day 10.5 (E10.5) Sprague-
Dawley rat spinal cord, as previously described [29,86].
NRP cells were prepared by inducing neuronal differen-
tiation from multipotent NEP cells, as described [29]. Glial-
restricted precursor cells (A2B5+ GRP) were isolated directly
from E13.5 Sprague-Dawley rat spinal cord [30]. Purified
O-2A/OPCs were prepared from the CC or optic nerve of
7-day-old Sprague-Dawley rats using a specific antibody
capture assay [42]. Purified oligodendrocytes were gener-
ated from O-2A/OPC cell cultures by growing cells in
presence of thyroid hormone (45 µM) to induce oligo-
dendrocyte differentiation [42]. Purified cortical astrocytes
were prepared from 1- to 2-day-old Sprague-Dawley rats as
described [87]. Multipotent and lineage committed human
embryonic neural progenitor cells were obtained from
Clonetics (San Diego, CA, USA) and propagated as
described previously [32,88].
Glioma cells and other cancer cell lines
Brain tumor cells used in this study were isolated from
patients with glioblastoma multiforme (1789, UT-12, UT-4
and T98 cell lines). Brain tumor cells were grown in serum-
free conditions in 50% chemically defined medium
(DMEM/F-12, supplemented with PDGF-AA and basic
fibroblast growth factor (FGF) at 10 ng/ml each) and 50%
astrocyte-conditioned medium (derived from cortical astro-
cyte cultures [87]). In addition, SW480 and HT-29 colon
carcinoma cells, uterine (MES), breast (MCF-7 and MDA-
MB-231), and ovarian cancer (ES-2) cells, L1210 lympho-
cytic leukemia and EL-4 lymphoma cells and a meningioma
cell line, derived from a patient with a meningothelio-
matous meningioma, were also evaluated. These cells were
propagated in DMEM/F-12 in presence of 5% FCS, except
for EL4 and L1210 (DMEM + 10% horse serum) and ES-2
(McCoy’s 5A (Cellgro) + 10% FCS). Sensitivity of cancer
cells to chemotherapeutic agents showed no significant
differences whether cells were assayed in the presence or
absence of serum.
In vitro toxicity and viability assay
For in vitro toxicity studies, cells were plated on coverslips at a
density of 1,000 cells per well. After 24-48 h, cells were
exposed to increasing drug concentrations of BCNU
(5-200 µM) for 1 h, cisplatin (0.1-100 µM) for 20 h or
cytarabine (0.01 µM to 2 µM) for 24 h. Cells were then
allowed to recover for 24-48 h, the times being based on
clinically applied dosages and elimination half-times of these
drugs in vivo. Cell survival and viability was determined using
the 3,(4,5-dimethylthiazol-2-yl) 2,5-diphenyl-tetrazolium-
bromide (MTT) assay in combination with 4,6-diamidino-2-
phenylindole (DAPI) staining to visualize DNA. The MTT
assay was performed as described and also combined with
immunofluorescence [89]. This assay is more sensitive than
the plate reader assay used in our previous studies on the
effects of BCNU on oligodendrocytes, O-2A/OPCs, and
astrocytes [22]. After MTT and DAPI staining, surviving cells
were determined by microscopically counting all individual
cells in control and treatment groups. All counting was done
blinded by a separate investigator. Each experiment was
carried out in quadruplicate and was repeated at least twice in
independent experiments. Data points represent mean from
single experiments and error bars shown in figures represent
± standard error of the mean (SEM).
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staining in vitro
Cell cultures were immunostained as described [29-32,41],
using the following antibodies: A2B5 mouse IgM mono-
clonal antibody (mAb) (Developmental Hybridoma Bank,
Iowa City, IA, USA); anti-galactocerebroside mouse IgG3
(GalC, 1:1, Developmental Hybridoma Bank, 1:50); anti-
GFAP polyclonal rabbit Ig (DAKO, Copenhagen, Denmark,
1:400); anti-neurofilament protein mouse mAb IgG1 (NF-L,
Chemicon, Temecula, CA, USA, 1:200), and anti-b-III-tubulin
mouse mAb IgG2b (Biogenex, San Ramon, CA, 1:400). Anti-
body binding was detected with appropriate fluorescent
dye-conjugated secondary antibodies (10 mg/ml, Southern
Biotechnology), or Alexa fluorophore-coupled antibodies at
a concentration of 1 µg/ml (Molecular Probes, Eugene, OR,
USA).
Chemotherapy application in vivo
For in vivo experiments, CBA mice at 6-8 weeks of age were
treated with chemotherapy under approved protocols.
BCNU, cisplatin, or cytarabine were administered via i.p.
injections. Animals received BCNU, cisplatin, or cytarabine
as three consecutive injections (3 × 10 mg/kg, 5 mg/kg, or
250 mg/kg body weight, respectively). Control animals
received equal amounts of 0.9% NaCl i.p. Animals were
sacrificed on days 1, 10, and 42 after completion of treat-
ment for cisplatin and BCNU (where day 0 equals the time
of the very last injection of the agent). For all in vivo
experiments, animals were perfused transcardially with 4%
paraformaldehyde in phosphate buffer (pH 7.4), under
deep anesthesia using Avertin (tribromoethanol; Sigma, St
Louis, MO, USA; 250 mg/kg, 1.2% solution).
Immunofluorescence and TUNEL staining in vivo
Free-floating sections (40 µm) were used for all in vivo
experiments for TUNEL staining and combined immuno-
fluorescence staining. Detection of nuclear profiles with
DNA fragmentation, one of the hallmarks of apoptosis, was
performed using a TUNEL assay on free-floating brain
sections based on the ApopTag-In-Situ Cell-Death-
Detection Kit (Intergene, Purchase, NY, USA), according to
the manufacturer’s recommendations. The TUNEL assay was
followed by DAPI counterstaining to visualize nuclear
profiles in all in vitro assays and when sections were
analyzed in a fluorescence microscope.
Briefly, sections were rinsed in TBS (0.9% NaCl and 0.1 M
Tris-HCl pH 7.5) for 10 min, then exposed to a series of
increasing concentrations of ethanol (50%, 70%, and 90%
for 2 min each), followed by a 10 min incubation in 100%
ethanol and a decreasing series of ethanol in 90%, 70%,
and 50% for 1 min each, followed by rinsing in distilled
water. After three rinses in TBS, the sections were exposed to
equilibration buffer for 1 min at room temperature, and
reaction buffer (TdT solution) for 1 h at 37°C, as per the
manufacturer’s recommendations. The reaction was termi-
nated using the Stop buffer for 10 min at room temperature.
Sections were rinsed 3× in TBS and 1× in TBS+ (TBS/0.1%
Triton X-100/3% donkey serum) for 1 h to reduce back-
ground staining. Fragmented DNA was detected by incu-
bation of sections in an anti-digoxigenin-FITC (fluorescein
isothiocyanate) antibody for 1 h at 4°C.
To combine TUNEL staining with immunofluorescence
staining for different cell-lineage markers, TUNEL staining
was carried out first, followed by exposure with either one
of the following primary antibodies for 24 to 48 h: mouse
anti-NeuN (1:500, Chemicon), mouse anti-DXC (double-
cortin) (1:500, Santa Cruz, Santa Cruz, CA, USA), rabbit
anti-active caspase-3 (1:1000, R&D systems, Minneapolis,
MN, USA), rat anti-S-100b (1:2500, Swant, Bellinzona,
Switzerland), rabbit anti-NG2 (1:2000, gift of William
Stallcup, Burnham Institute, La Jolla, CA, USA), mouse anti-
MBP (1:1000, Chemicon), mouse anti-CNPase (1:2000,
Sigma) and rabbit anti-GFAP (1:2500, DAKO). All
secondary antibodies, generated in donkey (anti-rat, anti-
rabbit, and anti-mouse), were coupled to TritC, FitC or Cy5
(Jackson Immuno Research, West Grove, PA, USA) for in
vivo staining and were used according to the species of
primary antibody. Free-floating sections were incubated
with secondary antibodies for 4 h in TBS+. All secondary
antibodies were used at a concentration of 1:500. After
several washes in TBS, sections were mounted on gelatin-
coated glass slides using Prolong Antifade mounting
medium (Molecular Probes).
Fluorescent signals were detected using a confocal laser-
scanning microscope Leica TCS SP2 (Heidelberg, Germany)
and a 40× oil-immersion lens. All fluorescent images were
generated using sequential laser scanning with only the
corresponding single wavelength laser line (488 nm,
568 nm, and 647 nm, for each fluorescent channel, respec-
tively), activated using acousto-optical tunable filters to
avoid cross-detection of either one of the fluorescence
channels. In addition, pinhole settings corresponding to an
optical thickness of less than 2 mm were used to avoid false-
positive signals from adjacent cells.
BrdU incorporation assay, BrdU labeling, and
immunoperoxidase staining for BrdU detection
To label the proportion of dividing cells engaged in DNA
synthesis  in vivo, mice received a single injection of
5-bromodeoxyuridine (50 mg/kg body weight), dissolved in
0.9% NaCl, filtered at 0.2 µm, and applied i.p. 4 h before
perfusion. Free-floating sections were treated with 0.6%
H2O2 in TBS (0.9% NaCl and 0.1 M Tris-HCl pH 7.5) for
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denaturation, sections were incubated for 2 h in 50%
formamide/2× SSC (0.3 M NaCl and 0.03 M sodium citrate)
at 65°C, rinsed for 5 min in 2× SSC, incubated for 30 min
in 2 N HCl at 37°C, and rinsed for 10 min in 0.1 M boric
acid pH 8.5. Several rinses in TBS were followed by
incubation in TBS/0.1% Triton X-100/3% donkey serum
(TBS+) for 30 min and incubation with rat anti-BrdU anti-
body (Harlan Sera Lab, Loughborough, UK, 1:2500) in TBS+
overnight at 4°C. Sections were rinsed in TBS+ and incu-
bated for 1 h with biotinylated donkey anti-rat antibody.
Sections were rinsed several times in TBS and avidin-biotin-
peroxidase complex (ABC system, Vector Laboratories,
Burlingame, CA, USA) was applied for 1 h, followed by
peroxidase detection for 5 min (0.25 mg/ml DAB, 0.01%
H2O2, 0.04% NaCl). After several washes in TBS, sections
were mounted on gelatin-coated glass slides using Prolong
Antifade mounting medium (Molecular Probes).
To analyze BrdU incorporation in specific cell types, anti-
BrdU immunostaining was combined with immuno-
labeling to identify DCX+ neuronal precursor cells, Olig2+
oligodendrocyte precursor cells (defined as cells that were
BrdU+ and Olig2+, in order to discriminate these cells from
Olig2+ nondividing oligodendrocytes [59-61]), and GFAP+
cells (which would have been astrocytes in the CC or DG or,
in the SVZ, may also have been stem cells). Labeling and
confocal analysis was carried out as for the combination of
immunolabeling with TUNEL staining. A minimum of 50
BrdU+ cells were counted for each labeling condition in
each animal (n = 3 animals in each group examined), with
the sole exception of the DG of the animals examined
56 days after cytarabine treatment (for which an identical
number of sections were examined as in control animals,
but the frequency of labeled cells was not sufficient to reveal
50 cells in these sections). Rabbit anti-Olig2 antibody was a
kind gift from David Rowitch.
Histology
Brains were cut coronally as 40-µm sections with a sliding
microtome (Leica, SM/2000R) and stored at -20°C in a
cryoprotectant solution (glycerol, ethylene glycol, and 0.1 M
phosphate buffer pH 7.4, 3:3:4 by volume). Quantification
of BrdU+ cells was accomplished with unbiased counting
methods. BrdU-immunoreactive nuclei were counted in one
focal plane to avoid oversampling. Brain structures were
sampled either by selecting predetermined areas on each
section (lateral subventricular zone = SVZ) or by analyzing
the entire structure on each section (CC, DG of the
hippocampus). Differences were considered significant
when p < 0.01. SVZ: BrdU+ cells were counted in every sixth
section (40 µm) from a coronal series between interaural
anterior-posterior (AP) +5.2 mm and AP +3.9 mm (the
anterior commissure crossing). BrdU+ cells were counted
along the lateral ventricular wall up to 200 mm from the
lateral ventricle wall. Corpus callosum (CC): BrdU+ cells
were counted in every sixth section (40 µm) from a coronal
series between interaural AP +5.2 mm and AP +3.0 mm in
the entire extension of the rostral and medial part of the CC
and analyzed as for SVZ. Dentate gyrus (DG) of hippo-
campus: BrdU+ cells were counted in every sixth section
(40 µm) from a coronal series between interaural AP
+2.5 mm and AP +1.1 mm. BrdU+ cells were counted in the
area of the DG, including the hilus, subgranular zone
(SGZ), and the granule cell layer (GCL) and analyzed as for
SVZ. Quantitative data in all figures is presented as mean
percentage normalized to control animals. Error bars
represent ± SEM.
Images and data processing and statistics
Digital images were captured using a Nikon Eclipse E400
upright microscope with a spot camera (Diagnostic Instru-
ments, Sterling Heights, MI, USA) and the spot advanced
software for Macintosh (Diagnostic Instruments), or using
the confocal laser-scanning microscope (Leica TCS SP2).
Photomicrographs were processed on a Macintosh G4 and
assembled with Adobe Photoshop 7.0 (Adobe Systems,
Mountainview, CA, USA). In all comparisons, unpaired,
two-tailed Student’s t-tests were used.
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